With simultaneous use of levodopa with beta-agonists, ditilin and drugs for inhalation anesthesia, the risk of developing heart rhythm disturbances may increase; with tricyclic antidepressants – decreased bioavailability of levodopa; with diazepam, clozapine, phenytoin, clonidine, m-cholinergic blockers, antipsychotic drugs (neuroleptics) – derivatives of butyrophenone, diphenylbutylpiperidine, thioxanthene, phenothiazine, as well as with pyridoxine, papaverine, reserpine, a decrease in the antiparkinsonian effect is possible; with lithium preparations the risk of developing dyskinesias and hallucinations increases; with methyldopa – worsening side effects.

When levodopa is used simultaneously with MAO inhibitors (except for MAO type B inhibitors), circulatory disorders are possible (taking MAO inhibitors should be discontinued 2 weeks before). This is due to the accumulation of dopamine and norepinephrine under the influence of levodopa, the inactivation of which is inhibited by MAO inhibitors, and a high likelihood of developing agitation, increased blood pressure, tachycardia, facial flushing and dizziness.

In patients receiving levodopa, the risk of a significant decrease in blood pressure increases when using tubocurarine.

Iron salts may reduce the bioavailability of levodopa and carbidopa; the clinical significance of this interaction is unknown.

Although metoclopramide increases the bioavailability of levodopa by accelerating gastric emptying, it may adversely affect disease control due to its antagonism at dopamine receptors.

Storage conditions

In a place protected from light and moisture at a temperature not exceeding 30 °C.

Shelf life

3 years

Manufacturer

Torrent Pharmaceuticals Ltd, India

Additional information

Shelf life	3 years
Conditions of storage	In a place protected from light and moisture at a temperature not exceeding 30 °C.
Manufacturer	Torrent Pharmaceuticals Ltd, India
Medication form	pills
Brand	Torrent Pharmaceuticals Ltd